Commonly used ulcer drugs may offer treatment potential in Alzheimer’s Disease

Amsterdam, 22 April 2009 – In a new study, published in the May issue of Elsevier’s  Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.
"Our results show that proton pump inhibitors are also antiinflammatory agents. They open up an entirely new application for these drugs" said Dr. Sadayuki Hashioka, first author on the paper.

Proton pump inhibitors include lansoprazole and omeprazole. They are remarkably safe drugs which have so far been used only to treat ulcers and other conditions where there is excess gastric acidity. These include Helicobacter pylori infections and side effects from treatment with NSAIDs such as ibuprofen. The finding that they also have anti-inflammatory potential opens up the possibility of using these drugs in a variety of inflammatory conditions where NSAIDs are now used. There would be the double effect of protection from gastrointestinal side effects plus enhanced antiinflammatory activity.

The researchers found that when human microglia, or human monocytic THP-1 cells, were exposed in vitro to the proton pump inhibitors, their secretions became less toxic towards human neuroblastoma cells. In addition, they found that these drugs acted synergistically with ibuprofen, a very widely used antiinflammatory agent. To confirm that the proton pump inhibitors were acting to inhibit inflammation, they found that lansoprazole and omeprazole reduced the secretion from THP-1 cells of the inflammatory cytokine tumor necrosis factor alpha.

Dr. Patrick McGeer, senior investigator on the UBC team, commented "Many epidemiological studies have revealed that individuals on long term treatment with ibuprofen are relatively spared from Alzheimer disease. Our investigation indicates that individuals taking lansoprezole or omeprazole in addition to ibuprofen might be getting even greater protection. It also suggests that a clinical trial of a combination of ibuprofen and a proton pump inhibitor might be effective for those already suffering from Alzheimer disease”.

Epidemiological studies might show a sparing effect of Alzheimer disease through the use of proton pump inhibitors alone".

The UBC study was supported by the Pacific Alzheimer Research Foundation.

# # #

Notes to Editors:
The full article is “Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity”, Experimental Neurology, Volume 217, Issue 1, pp. 177-183, available online 16 April 2009. Sadayuki Hashioka, Andis Klegeris, Patrick L. McGeer doi:10.1016/j.expneurol.2009.02.002

About the University of British Columbia
The University of British Columbia is the third largest University in Canada with its main campus being located in Vancouver Canada. It has over 40,000 students and more than 3000 full time faculty. The Medical Faculty enrolls 256 students per year. In 2006, the University was ranked second in Canada and twenty seventh in the world by Newsweek Magazine.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Jonathan Atkinson
Elsevier
+44 1865 843234
j.atkinson@elsevier.com